Business Wire

Global Two-Way Radio Communications Provider Hytera Sues Motorola Solutions for Patent Infringement

Jaa

Shenzhen, China-based Hytera Communications Corporation Limited, the world's leading provider of innovative professional mobile radio (PMR) solutions, today filed a lawsuit against Chicago, Ill.-based Motorola Solutions, Inc. in federal district court in Cleveland, Ohio, charging that Motorola Solutions is infringing Hytera's U.S. Patent No. 9,183,846, which covers its industry-leading sound adjustment control technology.

Hytera's '846 patent is its inventive method for adjusting sound volume in response to background or ambient noise, allowing a radio operator to hear and speak over it. The device obtains the current level of ambient noise, receives an instruction, and adjusts sound output. If ambient noise is high, the volume adjustment is greater at higher (treble) frequencies. Hytera's complaint asserts that Motorola Solutions unlawfully misappropriates Hytera’s patented technology for sound adjustment, incorporating it into its MOTOTRBO portable radios.

"Hytera has changed the landscape of the PMR business with its constant innovations, especially after its launch of a digital product line in 2010," said Tom Wineland, Director of Sales for Hytera Communications America (West), Inc. in Irvine, Calif. "Our patented sound adjustment functionality is one of the many innovations that Hytera has incorporated into our digital products, and users in markets around the world have embraced this feature."

Hytera's two-way radio communications equipment includes hand portables, mobiles, base stations, and dispatching and management software. Its products and solutions are used by commercial industries, such as energy companies and utilities, event organizers and producers, security and emergency management response teams, schools and other educational institutions, and public safety organizations. During use, personnel using Hytera's devices frequently move from quiet environments with little background noise to loud environments where machinery, engines, crowd noise, sirens, or other noises make it difficult to hear.

As embodied in the '846 patent, Hytera's sound adjustment capability is a key technological advance in PMR speaker design that is critical in a variety of noisy situations. "Our users—police and emergency responders, stadium and event managers, and commercial users—benefit greatly from this capability in our devices," adds Wineland.

"Motorola Solutions is infringing Hytera's sound adjustment control patent," said Andrew Yuan, Hytera's President of North and South America. "Hytera is a leader in innovative technologies, and an adamant advocate of intellectual property rights. We will look to enforce our patents in court in the U.S. and worldwide."

Hytera invests up to 15 percent of annual revenue in research and development, notes Yuan, including in open standard technologies, and is continually developing customized solutions that couple versatile LTE broadband for video and data transmission with traditional PMR narrow-band two-way voice communications. Hytera is one of the few companies worldwide that offers market-leading TETRA, DMR, and PDT technologies, and that offers products and solutions under all mainstream digital protocols. Hytera currently holds 480 issued patents, including 269 patents for digital products (DMR, TETRA, and PDT).

Hytera is the second-largest professional mobile radio communications solutions provider in the world, and the world’s fastest-growing. Hytera also is the world’s #1 DMR trunking provider. Hytera has partnered with companies in the U.S. since 2000, and established its first U.S. subsidiary, Hytera America, Inc., in 2004. Hytera established Hytera Communications America (West), Inc., in 2016 and opened research and equipment servicing facilities in the Chicago area this year.

Hytera further claims that Motorola has been and still is indirectly infringing Hytera's ‘846 Patent by actively inducing direct infringement by other persons who use products that embody one or more of the claims of the patent while Motorola had knowledge of the patent, knew or should have known that its actions would induce direct infringement by others, and intended that its actions would induce such direct infringement. Hytera is also alleging contributory infringement. Hytera is seeking damages and will pursue further relief as appropriate.

Hytera filed its lawsuit in the U.S. District Court for the Northern District of Ohio, in Cleveland, Ohio. The patent-at-issue is U.S. Patent No. 9,183,846 (“the ‘846 Patent”) titled “Method and Device for Adaptively Adjusting Sound Effect.” Hytera is represented in this action by Todd Tucker of Cleveland, Ohio-based law firm Calfee, Halter & Griswold LLP.

About Hytera Communications Corporation Limited

Founded in Shenzhen, China in 1993, Hytera Communications Corporation Limited is a closely-held privately-run company listed on the Shenzhen Stock Exchange (002583.SZ). With ten research and development centers around the world, Hytera is a leading global provider of innovative professional mobile radio (PMR) communications solutions to governmental organizations, public security institutions, and customers from other industries including transportation, oil and gas, and many others. Hytera aspires to leverage its technologies to improve organizational efficiency and make the world safer. Hytera's headquarters are at Hytera Tower, Shenzhen Hi-Tech Industrial Park North, Beihuan RD. 9108 Nanshan District, Shenzhen, P.R.C. In the U.S., the company has operations in Miramar, Fla., Irvine, Calif., and Chicago, Ill. More information is at www.hytera.com.

Contact information

Hytera Communications Corporation Limited
Johnny Jian
johnny.jian@hytera.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme